Business Context and Reporting Period
This Form 8-K was filed by Cyclacel Pharmaceuticals, Inc. (trading symbol: CYCC) on August 4, 2015. The report addresses a change in the listing status of the Company's common stock on The NASDAQ Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory listing status and compliance requirements.
Material Changes
- Listing Transfer: NASDAQ approved the transfer of the Company's common stock from the NASDAQ Global Market to the NASDAQ Capital Market, effective August 6, 2015.
- Reason for Transfer: The Company failed to meet the minimum bid price requirement of $1.00 per share under NASDAQ Listing Rule 5450(a)(1) as of February 2, 2015.
- Grace Period: Upon transfer, the Company received an additional 180-day grace period to regain compliance with the minimum bid price requirement.
Outlook, Risks, and Contingencies
Compliance Requirement: To avoid delisting, the Company must maintain a minimum bid price of at least $1.00 per share for at least ten consecutive business days during the new grace period, which ends on February 2, 2016.
Delisting Risk: If the Company fails to regain compliance by the end of the grace period, its common stock will be subject to delisting by NASDAQ.
Trading Status: The stock will continue to trade under the symbol "CYCC" on the NASDAQ Capital Market, which operates similarly to the Global Market but has different financial requirements.
Investor Verification Checklist
- Verify the current trading symbol (CYCC) and market (NASDAQ Capital Market) for the stock.
- Monitor the daily closing bid price to ensure it meets the $1.00 threshold for ten consecutive days before February 2, 2016.
- Review future filings for updates on the Company's progress toward regaining compliance with the minimum bid price requirement.
- Confirm that no other financial covenants or listing standards have been breached during the grace period.